No Data
No Data
Changes in Hong Kong stocks | CRO concept stocks declined in the afternoon, minutes of the Federal Reserve meeting, Phased adjustment of Eagle Pharmaceutical Investment and financing
The decline in CRO concept stocks widened in the afternoon. As of press release, Kanglong Chemical (03759) fell 3.99% to $10.58; Tiger Pharmaceuticals (03347) fell 3.93% to HK$34.25; and Kingsley Biotech (01548) fell 3.86% to $10.96.
Yao Ming Kangde (603259.SH) plans to subscribe for a share of an American private equity fund, which mainly invests in innovative biotechnology companies
Pharmaceutical Kangde (603259.SH) announced that WuXi PharmaTech, a wholly-owned subsidiary of the company...
Yao Ming Kangde (02359) spent about 27.4.31 million yuan to buy back 625,700 A shares on May 22
According to the Zhitong Finance App, Yao Ming Kangde (02359) announced that on May 22, 2024, the company spent about RMB 27.431 million to buy back 625,700 shares. The repurchase price was RMB 43.61 to $44.17 per share.
Moody's: Maintaining and Confirming Pharmaceutical Kangde (2359.HK/603259.SH) Baa2 Investment Grade Credit Rating
On May 21, Moody's maintained the issuer rating of Kantar Baa2, and the outlook was adjusted from stable to negative due to uncertainty brought about by proposed US legislation. Moody's said that the confirmation of Pharmaceutical Kangde Baa2 issuer rating reflects the company's leading market position as a contract research institution with a full-service new drug development and manufacturing service platform in China, its low debt leverage and excellent liquidity.
WuXi AppTec Executes Strategic Share Buybacks
Yao Ming Kangde (02359) spent about 20.084 million yuan to buy back 455.62 million A shares on May 21
According to the Zhitong Finance App, Yao Ming Kangde (02359) announced that on May 21, 2024, it spent about 20.084 million yuan to buy back 455.62 million A-shares.
No Data